Terms: = Bone cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Clinical Outcome
11 results:
1. Genetic variants of ctla4 are associated with clinical outcome of patients with multiple myeloma.
Gonzalez-Montes Y; Rodriguez-Romanos R; Villavicencio A; Osca-Gelis G; González-Bártulos M; Llopis F; Clapes V; Oriol A; Sureda A; Escoda L; Sarrà J; Garzó A; Lloveras N; Díez I; Granada I; Gallardo D
Front Immunol; 2023; 14():1158105. PubMed ID: 37122695
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic significance of PD-1, ctla-4, CD4, and CD8 expression in olfactory neuroblastoma.
Wu L; Liu H; Liu H
Clin Neuropathol; 2023; 42(2):47-53. PubMed ID: 36708210
[TBL] [Abstract] [Full Text] [Related]
3. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate clinical outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204
[TBL] [Abstract] [Full Text] [Related]
4. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract] [Full Text] [Related]
5. [Donor chimerism and minimal residual disease monitoring in leukemia patients after allo-HSCT].
Bogdanov KV; Motorin DV; Nikulina TS; Pisotskaya OS; Babenetskaya DV; Mirolyubova YV; Volkova OY; Zaritskiy AY
Biomed Khim; 2017 Nov; 63(6):570-581. PubMed ID: 29251621
[TBL] [Abstract] [Full Text] [Related]
6. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract] [Full Text] [Related]
7. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of ctla-4 expression on CLL cells: the possible implications for immunotherapy with ctla-4 blocking antibody.
Ciszak L; Frydecka I; Wolowiec D; Szteblich A; Kosmaczewska A
Tumour Biol; 2016 Mar; 37(3):4143-57. PubMed ID: 26490985
[TBL] [Abstract] [Full Text] [Related]
8. New therapeutic options for advanced non-resectable malignant melanoma.
Stadler S; Weina K; Gebhardt C; Utikal J
Adv Med Sci; 2015 Mar; 60(1):83-8. PubMed ID: 25596540
[TBL] [Abstract] [Full Text] [Related]
9. ctla-4 polymorphism and clinical outcome post allogeneic hematopoietic stem cell transplantation.
Mossallam GI; Samra MA
Hum Immunol; 2013 Dec; 74(12):1643-8. PubMed ID: 23973330
[TBL] [Abstract] [Full Text] [Related]
10. Syndecan-1 (CD 138) surface expression marks cell type and differentiation in ameloblastoma, keratocystic odontogenic tumor, and dentigerous cyst.
Al-Otaibi O; Khounganian R; Anil S; Rajendran R
J Oral Pathol Med; 2013 Feb; 42(2):186-93. PubMed ID: 22747594
[TBL] [Abstract] [Full Text] [Related]
11. [Giant cell tumor of bone. Morphological, immunohistochemical, morphometric and DNA flow cytometric findings].
Kröber SM; Greschniok A; Böhm P; Kaiserling E
Verh Dtsch Ges Pathol; 1998; 82():279-83. PubMed ID: 10095447
[TBL] [Abstract] [Full Text] [Related]
